Increasing Access to Lung Cancer Screening Act
HB6178, the Increasing Access to Lung Cancer Screening Act, would expand access to lung cancer screening and tobacco-cessation services across Medicaid, Medicare, and private health coverage. The bill requires state Medicaid plans to cover annual lung cancer screening for individuals recommended for screening under U.S. Preventive Services Task Force guidelines, with no cost sharing and no prior authorization. It also broadens Medicaid coverage of counseling and pharmacotherapy for tobacco cessation from pregnant women to all Medicaid enrollees, again prohibiting prior authorization for those services.
The bill also amends Medicare and private insurance rules to bar prior authorization for covered annual lung cancer screening. For Medicare Advantage plans and group or individual health plans, the measure would prohibit utilization-management barriers for screenings recommended under federal guidelines. In addition, it directs the Department of Health and Human Services to run a national education and outreach campaign focused on high-risk individuals and providers, authorizes $10 million annually from fiscal years 2026 through 2030 for that effort, and requires a GAO report on lung cancer demographics and populations that may be missed by current screening criteria.
The bill would change Title XIX of the Social Security Act by adding mandatory Medicaid coverage requirements for lung cancer screening and expanded tobacco-cessation treatment, and it would also affect Title XVIII and the Public Health Service Act by limiting prior authorization in Medicare and private insurance markets. States would generally have to implement the Medicaid changes beginning January 1, 2026, with a delayed compliance option if state legislation is needed. The measure would therefore affect state Medicaid programs, managed care organizations, Medicare Advantage plans, insurers, providers, and patients who are eligible for screening or cessation treatment.
Because there are no recorded votes or committee transcripts in the provided context, the overall sentiment cannot be measured from debate or roll call history. Based on the bill’s sponsors and its public-health framing, the measure appears to be presented as a preventive-care and access-expansion bill rather than a controversial benefit cut or regulatory rollback. The central policy theme is reducing barriers to early detection and smoking cessation, which generally suggests supportive intent.
The main points of contention likely concern federal mandates on state Medicaid programs and private plans, the elimination of prior authorization, and the costs of expanded coverage and outreach. Another possible issue is the bill’s reliance on USPSTF or Secretary-issued screening guidelines, which could raise questions about eligibility boundaries and whether some high-risk groups are excluded. The GAO report language specifically notes groups such as firefighters, veterans, and women under 50, indicating concern that current screening criteria may not capture all populations at risk.
The bill would amend the Social Security Act and the Public Health Service Act to require or prohibit certain coverage practices for lung cancer screening and tobacco-cessation services. It would impose new Medicaid benefit requirements, eliminate cost-sharing and prior authorization for specified screenings, expand cessation coverage to all Medicaid beneficiaries, and bar prior authorization in Medicare, Medicare Advantage, and private group and individual plans for covered annual lung cancer screening. It also creates a federally funded outreach program and a GAO study requirement, affecting federal agencies, state Medicaid programs, managed care organizations, insurers, providers, and eligible patients.
No committee transcript or vote data were provided, so there is no recorded legislative debate or roll-call sentiment to summarize. On its face, the bill is framed as a preventive-health access measure with bipartisan sponsorship and a focus on early detection and smoking cessation, which suggests generally favorable policy sentiment. The absence of recorded opposition in the supplied materials means any controversy is inferred from the policy design rather than from documented debate.
The likely areas of contention are the federal coverage mandates imposed on state Medicaid programs and private insurers, the prohibition on prior authorization, and the associated fiscal and administrative costs. States may object to the requirement to conform their Medicaid plans, especially where state legislation is needed, while insurers and managed care organizations may resist limits on utilization management. There may also be debate over whether the screening criteria are broad enough, since the bill’s own report language highlights populations such as firefighters, veterans, and women under 50 who may not be fully captured by current guidelines.